ATE241141T1 - Behandlung und diagnose helicobacter pylori infektionen - Google Patents

Behandlung und diagnose helicobacter pylori infektionen

Info

Publication number
ATE241141T1
ATE241141T1 AT96939221T AT96939221T ATE241141T1 AT E241141 T1 ATE241141 T1 AT E241141T1 AT 96939221 T AT96939221 T AT 96939221T AT 96939221 T AT96939221 T AT 96939221T AT E241141 T1 ATE241141 T1 AT E241141T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
pct
helicobacter pylori
pylori infections
Prior art date
Application number
AT96939221T
Other languages
English (en)
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE241141T1 publication Critical patent/ATE241141T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96939221T 1995-12-06 1996-11-27 Behandlung und diagnose helicobacter pylori infektionen ATE241141T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9524934A GB2307987A (en) 1995-12-06 1995-12-06 Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
PCT/GB1996/002907 WO1997021103A1 (en) 1995-12-06 1996-11-27 Treatment and diagnosis of infections due to helicobacter pylori

Publications (1)

Publication Number Publication Date
ATE241141T1 true ATE241141T1 (de) 2003-06-15

Family

ID=10784993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939221T ATE241141T1 (de) 1995-12-06 1996-11-27 Behandlung und diagnose helicobacter pylori infektionen

Country Status (10)

Country Link
US (1) US6039959A (de)
EP (1) EP0876613B1 (de)
JP (1) JP4219402B2 (de)
AT (1) ATE241141T1 (de)
AU (1) AU7635396A (de)
CA (1) CA2239208C (de)
DE (1) DE69628336T2 (de)
ES (1) ES2200077T3 (de)
GB (1) GB2307987A (de)
WO (1) WO1997021103A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
JP3430853B2 (ja) 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
EP1125130B1 (de) * 1998-10-29 2006-07-26 DakoCytomation Denmark A/S Nachweis von säure-resistenten mikroorganismen im stuhl
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
DE10032538A1 (de) * 2000-07-05 2002-01-17 Max Planck Gesellschaft Vakzine gegen Helicobacter pylori
WO2002005845A1 (en) * 2000-07-05 2002-01-24 Merieux Oravax Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
CA2351110A1 (en) * 2000-07-17 2002-01-17 Akzo Nobel N.V. Helicobacter felis vaccine
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
FI118061B (fi) * 2001-09-24 2007-06-15 Beanor Oy Menetelmä ja bioanturi analyysiä varten
US6929926B2 (en) 2001-10-15 2005-08-16 Barry J. Marshall Composition for the detection of gastrointestinal disorders
US7008777B2 (en) 2001-10-15 2006-03-07 Barry J. Marshall System for the detection of urease and method for using same
US20030072686A1 (en) * 2001-10-15 2003-04-17 Marshall Barry J. Systems for performing multiple diagnostic tests
US6998250B2 (en) 2001-10-15 2006-02-14 Donald J. McMichael Method for detecting Helicobacter pylori
US20030073155A1 (en) * 2001-10-15 2003-04-17 Mcmichael Donald J. Methods for performing multiple diagnostic tests
USD484988S1 (en) 2001-12-17 2004-01-06 Kimberly-Clark Worldwide, Inc. Diagnostic test kit with specimen-handling tool
US6783976B2 (en) 2001-12-21 2004-08-31 Kimberly-Clark Worldwide, Inc. Carrier and specimen-handling tool for use in diagnostic testing
FI115166B (fi) * 2001-12-31 2005-03-15 Biofons Oy Diagnostisia menetelmiä
CN117050168B (zh) * 2023-08-14 2024-03-01 苏州东抗生物科技有限公司 抗幽门杆菌UreA蛋白的单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
AU4924893A (en) * 1992-09-16 1994-04-12 Galagen, Inc. Antibody treatment of (helicobacter pylori)
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
WO1995014093A1 (en) * 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
WO1997021103A1 (en) 1997-06-12
US6039959A (en) 2000-03-21
EP0876613B1 (de) 2003-05-21
AU7635396A (en) 1997-06-27
CA2239208C (en) 2011-01-04
DE69628336T2 (de) 2004-04-01
ES2200077T3 (es) 2004-03-01
CA2239208A1 (en) 1997-06-12
GB9524934D0 (en) 1996-02-07
JP4219402B2 (ja) 2009-02-04
EP0876613A1 (de) 1998-11-11
DE69628336D1 (de) 2003-06-26
JP2000502070A (ja) 2000-02-22
GB2307987A (en) 1997-06-11

Similar Documents

Publication Publication Date Title
ATE241141T1 (de) Behandlung und diagnose helicobacter pylori infektionen
DE69720058D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
DE69726195D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
DE69626227D1 (de) Hierarchisches regelbasiertes system zur diagnose und behandlung von arrythmien
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
HUP0101719A2 (hu) Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával
ATE346867T1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
DE69226775D1 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
DE60226324D1 (de) Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DE59504430D1 (de) Orales echokontrastmittel für ultraschalldiagnostik
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
ATE473295T1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
HUP0100887A2 (hu) Bibapcitid-bázisú gyógyszerkészítmények trombusok leképezésére és kezelésére
UA30274A (uk) Спосіб діагностики носійства токсогенного штаму дифтерійної палички
UA33330A (uk) Спосіб діагностики ендогенної інтоксикації

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties